R-2HGは,FTO/m6A/MYC/CEBPAシグナリングをターゲットにすることで,抗腫瘍活性を示す
Rui Su1, Lei Dong1, Chenying Li2
1Department of Cancer Biology, University of Cincinnati, Cincinnati, OH 45219, USA.
Cell
|December 19, 2017
まとめ
変異したIDH1/ 2酵素の代謝物であるR- 2ヒドロキシグルタレート (R- 2HG) は,FTOを阻害し,MYC/ CEBPAの安定性を低下させることで,抗白血病効果を示す. この代謝物はまた,瘤における抗腫瘍作用を示している.
科学分野:
- 生物化学
- 腫瘍学
- 分子生物学
背景:
- 変異したイソチラート脱水素酵素1/ 2 (IDH1/ 2) は,以前にオンコメタボライトとして特定されたR- 2ヒドロキシグルタレート (R- 2HG) を上昇させます.
- R-2HGの癌における役割,特にその潜在的な治療用途については,さらなる調査が必要である.
研究 の 目的:
- R-2HGの抗白血病および抗腫瘍作用を調査する.
- 癌細胞に対するR-2HGの作用の分子メカニズムを解明する.
主な方法:
- 白血病と膠原腫のモデルを用いた in vitro および in vivo 実験
- 細胞増殖,生命力,細胞サイクル停止,アポトーシスの評価
- FTOの活性,m6ARNAの変異レベル,MYC/CEBPAのトランスクリプトの安定性の分析
主要な成果:
- R- 2HGは,増殖を抑制し,細胞サイクル停止を誘導し,アポトーシスを促進することによって,広範な抗白血病活性を示した.
- R- 2HGは脂肪量と肥満に関連したタンパク質 (FTO) の活性を抑制し,m6ARNAの改変を増加させます.
- このメカニズムはMYC/CEBPAのトランスクリプトの安定性を低下させ,腫瘍的経路を抑制する.変異したIDH1およびS- 2HGで同様の効果が観察された.
- 高レベルのFTOは細胞をR- 2HGに敏感にし,MYCの過剰活性化により抵抗性が生じ,MYCの抑制によって逆転する.
- また,R- 2HGは膠原腫における抗腫瘍作用を示した.
結論:
- R- 2HGは,FTO/ m6A/ MYC/ CEBPAシグナル伝達経路を標的にすることで,白血病と膠原腫に対する有意な抗腫瘍特性を示しています.
- R- 2HGはIDH1/ 2変異性がんの発症に寄与しますが,FTOの高いがん細胞の増殖と生存を抑制することで治療的可能性も持っています.
- これらの発見は,R- 2HGを潜在的治療薬として強調し,がんの進行と治療におけるメタボリットの複雑な役割を強調しています.
関連する概念動画
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Mitogens and the Cell Cycle
8.2K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K


